NCT00038961View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Fondaparinux Sodium When Used With Intermittent Pneumatic Compression to Prevent Venous Thromboembolic (IPC) Versus IPC Alone for the Prevention of Venous Thromboembolic Events in Subjects at Increased Risk Undergoing Major Abdominal Surgery (APOLLO).

PHASE3CompletedINTERVENTIONAL

Enrollment

1,309

Participants

Timeline

Start Date

November 30, 2001

Primary Completion Date

October 31, 2004

Study Completion Date

October 31, 2004

Conditions

Thromboembolism

Interventions

DRUG

fondaparinux sodium

2.5 mg fondparinux sodium, daily, s.c. starting 6 to 8 hours after surgical closure for up to 7 +/- 2 days, administered on top of IPC +/- elastic stockings (ES)

OTHER

placebo

placebo, daily, s.c. starting 6 to 8 hours after surgical closure for up to 7 +/- 2 days, administered on top of IPC +/- elastic stockings (ES)